丹参酮ⅡA联合维拉帕米对冠心病心绞痛患者炎性因子及SAQ评分的影响

Effect of tanshinoneⅡA combined with verapamil on inflammatory factors and SAQ score in patients with angina pectoris of coronary heart disease

目的观察丹参酮ⅡA联合维拉帕米对冠心病心绞痛患者炎性因子及西雅图心绞痛量表(SAQ)评分的影响。方法回顾性选取2018年10月—2020年11月北京王府中西医结合医院收治的冠心病心绞痛患者120例,按照治疗方案不同分为观察组和对照组,各60例。在常规治疗基础上,对照组给予维拉帕米治疗,观察组给予丹参酮ⅡA联合维拉帕米治疗,2组均治疗4周。比较2组治疗前后SAQ评分、炎性因子[脂蛋白相关磷脂酶A2(Lp-PLA2)、超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)]水平、心肌酶[肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)]水平及血管内皮功能指标[一氧化氮(NO)、血栓调节蛋白(TM)]。结果治疗4周后,2组发作情况、躯体受限及稳定状态评分均较治疗前升高,且观察组大于对照组(P<0.05或P<0.01);2组Lp-PLA2、hs-CRP、IL-6水平及CK、CK-MB、LDH水平均较治疗前降低,且观察组低于对照组(P<0.05或P<0.01);2组NO、TM水平均较治疗前升高,且观察组高于对照组(P均<0.01)。结论丹参酮ⅡA联合维拉帕米治疗冠心病心绞痛可有效改善患者血管内皮功能、心肌酶水平及SAQ评分,同时更好地缓解患者炎性应激状态,值得推广。

Objective To observe the effect of tanshinoneⅡA combined with verapamil on inflammatory factors and the score of Seattle angina questionnaire(SAQ)in patients with angina pectoris of coronary heart disease.Methods Retrospective selection of 120 patients with angina pectoris of coronary heart disease admitted to Beijing Royal Integrative Medicine Hospital from October 2018 to November 2020,according to different treatment plans,they were divided into observation group and control group,with 60 patients in each group.On the basis of routine treatment,the control group was treated with verapamil,and the observation group was treated with tanshinoneⅡA combined with verapamil,both groups were treated for 4 weeks.Compared the SAQ score,inflammatory factors[lipoprotein related phospholipase A2(Lp-PLA2),hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)],myocardial enzymes[phosphocreatine kinase(CK),phosphocreatine isoenzyme(CK-MB),lactate dehydrogenase(LDH)],and vascular endothelial function indexes[nitric oxide(NO),thrombomodulin(TM)]before and after treatment in two groups.Results After 4 weeks of treatment,the seizure status,physical limitations,and stable state scores of the two groups increased compared to before treatment,and the observation group was higher than the control group(P<0.05 or P<0.01);The levels of Lp-PLA2,hs-CRP,IL-6,CK,CK-MB,and LDH in the two groups decreased compared to before treatment,and the observation group was lower than the control group(P<0.05 or P<0.01);The levels of NO and TM in the two groups increased compared to before treatment,and the observation group was higher than the control group(all P<0.01).Conclusion TanshinoneⅡA combined with verapamil in the treatment of angina pectoris of coronary heart disease can effectively improve the vascular endothelial function,myocardial enzyme level and SAQ score of patients,and can more effectively alleviate the inflammatory stress state of patients,which is worth promoting.